Compare
BullFrog AI Holdings, Inc. vs Serina Therapeutics, Inc. vs iBio, Inc. vs Actinium Pharmaceuticals, Inc.
| Latest fiscal year | BullFrog AI Holdings, Inc. BFRG | Serina Therapeutics, Inc. SER | iBio, Inc. IBIO | Actinium Pharmaceuticals, Inc. ATNM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $116.7K | $130.0K | $100.0K | $90.0K |
| Revenue growth (YoY) | n/a | +132.1% | -75.0% | n/a |
| Gross margin | 18.8% | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$6.50M | -$19.18M | -$33.04M | -$33.89M |
| EPS (Diluted) | -$0.63 | -$1.91 | -$0.32 | -$1.09 |
| Operating cash flow | -$5.52M | -$17.95M | -$23.22M | -$24.58M |
| Free cash flow | n/a | -$18.01M | -$23.80M | -$24.68M |
| Cash & equivalents | $2.18M | $3.06M | $56.40M | $48.00M |
| Total assets | $2.81M | $6.95M | $99.11M | $51.77M |
| Total liabilities | $672.0K | $6.99M | $13.40M | $43.94M |
| Shareholders' equity | $2.14M | -$37.0K | $85.71M | $7.83M |
| Return on year-end equity | -304.2% | n/a | -38.6% | -432.6% |
| Shares outstanding | 11.42M | 10.77M | 55.70M | 31.20M |
Revenue, most recent five fiscal years
| Fiscal year | BullFrog AI Holdings, Inc. | Serina Therapeutics, Inc. | iBio, Inc. | Actinium Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $116.7K Ended 2025-12-31 | $130.0K Ended 2025-12-31 | $100.0K Ended 2026-06-30 | $90.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $56.0K Ended 2024-12-31 | $400.0K Ended 2025-06-30 | n/a |
| 2 years earlier | $65.0K Ended 2023-12-31 | $3.15M Ended 2023-12-31 | $225.0K Ended 2024-06-30 | $81.0K Ended 2023-12-31 |
| 3 years earlier | $10.0K Ended 2022-12-31 | $34.0K Ended 2022-12-31 | $0 Ended 2023-06-30 | $1.03M Ended 2022-12-31 |
| 4 years earlier | n/a | $144.0K Ended 2021-12-31 | $1.88M Ended 2022-06-30 | $1.14M Ended 2021-12-31 |